Anzeige
Mehr »
Login
Dienstag, 01.04.2025 Börsentäglich über 12.000 News von 695 internationalen Medien
Kurs-Explosion voraus?: Diese kaum bekannte Aktie bohrt jetzt im Hotspot - und du erfährst es als Erster!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EGXK | ISIN: SE0020353928 | Ticker-Symbol: MB8
Frankfurt
01.04.25
09:17 Uhr
0,674 Euro
+0,008
+1,13 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
MOBERG PHARMA AB Chart 1 Jahr
5-Tage-Chart
MOBERG PHARMA AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,7110,74021:47
0,7190,74021:47

Aktuelle News zur MOBERG PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.02.Moberg Pharma AB: Moberg Pharma Year-end report 2024135TERCLARA CONTINUES TO LEAD THE MARKET AND EXPANDS TO NORWAY THE YEAR (JAN-DEC 2024) Net revenue SEK 9.8 million (0) EBITDA SEK -23.5 million (-25.4) Operating profit (EBIT) SEK -324.8 million...
► Artikel lesen
MOBERG PHARMA Aktie jetzt für 0€ handeln
03.02.MOBERG PHARMA: Terclara (MOB-015) is now being launched in Norway3
18.12.24MOBERG PHARMA: New terbinafine supplier secured2
10.12.24Cipher Pharmaceuticals Partner Moberg Pharma AB Reports Topline Data in MOB-015 Phase 3 Study8
10.12.24Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU155STOCKHOLM, Dec. 10, 2024 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in the phase...
► Artikel lesen
12.11.24Moberg Pharma AB: Moberg Pharma's Interim report January - September 2024152TERCLARA WINS LAUNCH OF THE YEAR AT KRONANS PHARMACY AND DOZ PHARMACY NINE-MONTH PERIOD (JAN-SEP 2024) Net income SEK 8.8 million (0) EBITDA SEK -15.7 million (-17.4) Operating profit (EBIT) SEK...
► Artikel lesen
08.11.24Moberg Pharma's Nomination Committee appointed4
13.09.24Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients297STOCKHOLM, Sept. 13, 2024 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in the ongoing North American...
► Artikel lesen
13.08.24Moberg Pharma AB: Moberg Pharma's interim report January - June 2024163TERCLARA IS THE MARKET LEADER IN SWEDEN SIX-MONTH PERIOD (JAN-JUNE 2024) Net revenue SEK 4.9 million (0) EBITDA SEK -12.7 million (-10.7) Operating profit (EBIT) SEK -13.4 million (-12.0) Profit...
► Artikel lesen
24.06.24Moberg Pharma AB: Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%323("Moberg Pharma" or the "Company") announces that 17,776,856 warrants of series 2023:1 ("TO 2") were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million...
► Artikel lesen
07.05.24Moberg Pharma AB: Moberg Pharma's interim report January - March 2024524LAUNCH INITIATED IN SWEDEN FIRST QUARTER (JAN-MAR 2024) Net revenue SEK 0.8 million (0) EBITDA SEK -7.6 million (-6.1) Operating profit (EBIT) SEK -7.9 million (-6.7) Profit after tax SEK -6.5...
► Artikel lesen
11 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1